31
Oct
2019

Amgen’s Bet on BeiGene, David Hung’s Megaround, & Zolgensma Speed Bump

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

A Baffling Coronavirus Response, Arch & Flagship Reload, & Merck Passes 2 Phase IIIs
The Coronavirus Tsunami, Lyell’s $492M Megaround & Some Deals You Missed
COVID-19: Collective Problem-Solving Time
COVID-19 Spreads in Seattle, Gilead’s $4.9B Cancer Bet, & Thermo Grabs Qiagen